vTv Therapeutics(VTVT) - 2025 Q3 - Quarterly Results

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 Exhibit 99.1 vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousan ...